General Nieuws Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria EN september 17, 2018
General Nieuws Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website EN september 10, 2018
General Nieuws ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) EN juli 19, 2018
General Nieuws ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC EN juni 21, 2018
General Nieuws ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) EN mei 25, 2018
General Nieuws ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 EN mei 23, 2018
General Nieuws ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN mei 14, 2018
Nieuws Regulated Transparency/Denominator Regulated Information / Transparency Statement EN NL april 27, 2018
General Nieuws ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME EN april 27, 2018
General Nieuws ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 EN april 6, 2018
General Nieuws ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) EN april 4, 2018
General Nieuws Regulated Disclosure in accordance with Belgian Law of 2 May 2007 EN NL januari 30, 2018
Nieuws Regulated Transparency/Denominator NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL EN NL januari 26, 2018
General Nieuws Regulated ThromboGenics – Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate EN december 8, 2017
